Abstracts tagged "immunoglobulin (IG) and citrullination"

Abstract Number: 482 • 2019 ACR/ARP Annual Meeting
Antibody Repertoire Sequencing, Antigen Array Analysis, and Cytokine Profiling of Blood from Individuals at High-risk for RA Reveals Candidate Immunoglobulin V Genes, ACPA, and Cytokines That May Promote the Transition to Arthritis
Radhika Iyer¹, Amin Zia ¹, Michelle Bloom ¹, Sunil Nagpal ², Navin Rao ², Frédéric Baribaud ³, George Vratsanos ⁴, Wei Wang ⁵, Gary Firestein ⁶, David Boyle ⁵, Jane Buckner ⁷, V. Michael Holers ⁸, Kevin Deane ⁹ and William Robinson ¹⁰, ¹Stanford University, Stanford, ²Janssen R&D, Spring House, PA, ³Janssen Research & Development, LLC, Spring House, PA, ⁴JNJ, Raritan, NJ, ⁵University of California, San Diego, San Diego, CA, ⁶University of California, San Diego, San Diego, ⁷Benaroya Research Institute, Seattle, WA, ⁸University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver, ⁹University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, ¹⁰Stanford University, Stanford, CA
Background/Purpose: The “Targeting Immune Responses for Prevention of RA” (TIP-RA) collaboration studies individuals at high risk for developing rheumatoid arthritis (RA) because of serum anti-citrullinated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].